» Articles » PMID: 26662989

MicroRNA and Cardiac Regeneration

Overview
Date 2015 Dec 15
PMID 26662989
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Heart diseases are a very common health problem in developed as well as developing countries. In particular, ischemic heart disease and heart failure represent a plague for the patients and for the society. Loss of cardiac tissue after myocardial infarction or dysfunctioning tissue in nonischemic cardiomyopathies may result in cardiac failure. Despite great advancements in the treatment of these diseases, there is a substantial unmet need for novel therapies, ideally addressing repair and regeneration of the damaged or lost myocardium. Along this line, cardiac cell based therapies have gained substantial attention. Three main approaches are currently under investigation: stem cell therapy with either embryonic or adult stem cells; generation of patient-specific induced pluripotent stem cells; stimulation of endogenous regeneration trough direct reprogramming of fibroblasts into cardiomyocytes, activation of resident cardiac stem cells or induction of native resident cardiomyocytes to reenter the cell cycle. All these strategies need to be optimized since their efficiency is low.It has recently become clear that cardiac signaling and transcriptional pathways are intimately intertwined with microRNA molecules which act as modulators of cardiac development, function, and disease. Moreover, miRNA also regulates stem cell differentiation. Here we describe how miRNA may circumvent hurdles that hamper the field of cardiac regeneration and stem cell therapy, and how miRNA may result as the most suitable solution for the damaged heart.

Citing Articles

Circulating microRNAs and cardiomyocyte proliferation in heart failure patients related to 10 years survival.

Wagh V, Nguemo F, Kiseleva Z, Mader R, Hescheler J, Mohl W ESC Heart Fail. 2023; 10(6):3559-3572.

PMID: 37752740 PMC: 10682869. DOI: 10.1002/ehf2.14516.


The long non-coding road to endogenous cardiac regeneration.

Afify A Heart Fail Rev. 2019; 24(4):587-600.

PMID: 30900115 DOI: 10.1007/s10741-019-09782-5.


mi R -15a/15b Cluster Modulates Survival of Mesenchymal Stem Cells to Improve Its Therapeutic Efficacy of Myocardial Infarction.

Tu Y, Qiu Y, Liu L, Huang T, Tang H, Liu Y J Am Heart Assoc. 2019; 8(1):e010157.

PMID: 30616426 PMC: 6405735. DOI: 10.1161/JAHA.118.010157.


Impact of Biomaterials on Differentiation and Reprogramming Approaches for the Generation of Functional Cardiomyocytes.

Paoletti C, Divieto C, Chiono V Cells. 2018; 7(9).

PMID: 30134618 PMC: 6162411. DOI: 10.3390/cells7090114.


Circulating miR-23b as a Novel Biomarker for Early Risk Stratification After ST-Elevation Myocardial Infarction.

Zhang J, Li Y, Zhao Q Med Sci Monit. 2018; 24:1517-1523.

PMID: 29535290 PMC: 5866732. DOI: 10.12659/msm.908060.